As filed with the Securities and Exchange Commission on April 5, 2024.
Registration No. 333-264463
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST - EFFECTIVE AMENDMENT NO. 2
TO
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
bioAffinity Technologies, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 8731 | 46-5211056 | ||
(State or other jurisdiction of incorporation or organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification Number) |
22211 W Interstate 10
Suite 1206
San Antonio, Texas 78257
(210) 698-5334
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Maria Zannes
Chief Executive Officer
22211 W Interstate 10
Suite 1206
San Antonio, Texas 78257
(210) 698-5334
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Leslie Marlow, Esq.
Melissa Palat Murawsky, Esq.
Blank Rome LLP
1271 Avenue of the Americas
New York, New York 10020
Tel: (212) 885-5000
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Accelerated filer ☐ | |
Non-accelerated filer ☒ | Smaller reporting company ☒ | |
Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY NOTE
This Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 of bioAffinity Technologies, Inc. (the “Company”), as originally declared effective by the Securities and Exchange Commission (the “SEC”) on August 29, 2022, is being filed for the sole purpose of filing Exhibit 5.2 as part of the Registration Statement. This Post-Effective Amendment No. 2 does not modify any provision of Part I or Part II of the Registration Statement other than supplementing Item 16 of Part II as set forth below.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 16. Exhibits and Financial Statement Schedules.
(a) | Exhibits |
See the Exhibit Index immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement on Form S-1, which Exhibit Index is incorporated herein by reference.
(b) | Financial Statement Schedules |
Schedules not listed have been omitted because the information required to be set forth therein is not applicable, not material or is shown in the financial statements or notes thereto.
EXHIBIT INDEX
II-1 |
II-2 |
* | Filed herewith. |
** | Previously filed |
+ | Indicates management contract or compensatory plan. |
II-3 |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Post Effective Amendment No. 2 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of San Antonio, Texas, on April 5, 2024.
bioAffinity Technologies, Inc. | ||
By: | /s/ Maria Zannes | |
Maria Zannes | ||
Chief Executive Officer, President, Founder, and Director |
Signature | Title | Date | ||
/s/ Maria Zannes | Founder, President, Chief Executive Officer, and Director (Principal Executive Officer) | April 5, 2024 | ||
Maria Zannes | ||||
* | Chief Financial Officer | April 5, 2024 | ||
Michael Dougherty | (Principal Financial and Accounting Officer) | |||
* | Founder, Executive Chairman, and Director | April 5, 2024 | ||
Steven Girgenti | ||||
* | Director | April 5, 2024 | ||
Robert Anderson | ||||
* | Director | April 5, 2024 | ||
Stuart Diamond | ||||
* | Director | April 5, 2024 | ||
Peter S. Knight | ||||
* | Director | April 5, 2024 | ||
Gary Rubin | ||||
* | Director | April 5, 2024 | ||
Roby Joyce | ||||
* | Director | April 5, 2024 | ||
Jamie Platt |
*By: | /s/ Maria Zannes | |
Maria Zannes, Attorney-In-Fact |
II-4 |